Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-15

Study Completion Date

2020-09-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Researchers in this study want to learn about the safety of drug BAY1817080 at different doses and the resulting blood levels of the study drug in Japanese healthy adult male participants. Study drug BAY1817080 is a drug under development with a goal to suppress pain and chronic cough. It works by binding to and blocking proteins expressed on the sensory nerves of the womb tissue, bladder or airway which are oversensitive in the patients with endometriosis (a condition where the tissue that usually grows inside the womb grows outside of the womb), overactive bladder (a condition that causes a sudden urge to urinate often or more frequently) and long-standing cough with or without clear causes.

Participants in this study will receive either the study drug or placebo tablets (a placebo looks like the test drug but does not have any medicine in it). The dosage will be either one single dose of study drug/placebo received on only one day or multiple doses of study drug/placebo received twice daily for 13 days plus one dose in the morning of the 14th day. The total study duration for each participant will be usually no more than 42 days. Blood samples will be collected from the participants to monitor the safety and measure the blood level of the study drug.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain

NCT04641273

Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

TERMINATED PHASE2

A Study to Learn How Safe the Study Treatment BAY2395840 is, How it Affects the Body and How it Moves Into, Through, and Out of the Body if Given in Single and in Repetitive Doses to Japanese Healthy Male Participants

NCT05563454

Diabetic Neuropathic Pain Healthy Volunteers

COMPLETED PHASE1

A Study to Learn How Safe BAY2395840 is and How Well it Works in Participants Who Have Diabetic Nerve Pain

NCT05219812

Neuropathic Pain Associated With Diabetic Peripheral Neuropathy Peripheral Neuropathic Pain Diabetes Mellitus

COMPLETED PHASE2

Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy

NCT00307749

Diabetic Polyneuropathy

COMPLETED PHASE2

A Study to Assess the Safety of MEB-1170 in Healthy Subjects

NCT05748119

Pain

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endometriosis Related Pain Overactive Bladder Diabetic Neuropathic Pain Refractory or Unexplained Chronic Cough

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dose escalation BAY1817080

Participants receive dose 1 to 3 of BAY1817080 as a single dose on Day 1.

Group Type EXPERIMENTAL

BAY1817080

Intervention Type DRUG

Three different doses over the course of study

Dose expansion BAY1817080

Participants receive the highest dose 3 of BAY1817080 twice daily (BID) from Day 1 until Day 13 and a single dose on Day 14.

Group Type EXPERIMENTAL

BAY1817080

Intervention Type DRUG

Three different doses over the course of study

Dose escalation Placebo

Participants receive placebo tablets orally as a single dose on Day 1.

Group Type PLACEBO_COMPARATOR

Matching Placebo

Intervention Type DRUG

Matching Placebo to BAY1817080

Dose expansion Placebo

Participants receive placebo tablets as BID multiple doses from Day 1 until Day 13 and as a single dose on Day 14.

Group Type PLACEBO_COMPARATOR

Matching Placebo

Intervention Type DRUG

Matching Placebo to BAY1817080

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BAY1817080

Three different doses over the course of study

Intervention Type DRUG

Matching Placebo

Matching Placebo to BAY1817080

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant must be 20 to 45 years of age inclusive, at the time of signing the informed consent.
* Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs, laboratory tests, and ECG.
* Non-smoker for at least 6 months and with a pack year history of equal to or less than 5 years
* Race: Japanese.
* BMI: above or equal 18.0 and below or equal 30.0 kg/m² at the screening visit.
* Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
* Men of reproductive potential must agree to use adequate contraception when sexually active. This applies for the time period between signing of the ICF and 90 days after the last administration of study intervention.

Exclusion Criteria

* Any findings from the medical examination (including medical history, physical examination, vital signs, laboratory tests and ECG) deviating from normal and deemed by the investigator to be of clinical relevance
* Relevant diseases potentially interfering with the study objectives within the 4 weeks before screening or between screening and randomization
* Any febrile illness within the four weeks before screening or between screening and randomization
* Any known presence or history of severe allergies, non-allergic drug reactions, or multiple drug allergies
* Known or suspected malignant tumors or carcinoma in situ
* Any history of malignant tumors
* Any known or suspected benign tumors of the liver and/or pituitary gland
* Known liver disease: existing acute or chronic progressive liver disease, e.g. disturbance of bilirubin excretion (Dubin-Johnson and Rotor syndromes); disturbances of bile secretion and flow (cholestasis); presence or history of liver tumors (benign or malignant). Note: According to this criterion there must have been an interval of at least 6 months between the subsidence of any viral hepatitis (normalization of liver parameters) and the screening visit.

Minimum Eligible Age

20 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes